Eliah R. Shamir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eliah R. Shamir has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Josef Ewald
Johns Hopkins University 1 Department of Cell Biology, School of Medicine Baltimore, Maryland
8 shared publications Gregor Krings
2 shared publications- Gregor Krings
Cleveland Clinic, Cleveland, OH
2 shared publications Kester Coutinho
Departments of Cell Biology and Oncology, Center for Cell Dynamics, Johns Hopkins University School of Medicine, 855 N. Wolfe St, Baltimore, MD 21205, USA Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS Donner, Berkeley, CA 94720, USA
2 shared publicationsKevin A. Marroquin
Genentech, South San Francisco, CA, USA
2 shared publicationsKevin J. Cheung
Center for Cell Dynamics, Johns Hopkins School of Medicine
2 shared publications
Latest Publications
- 28 August 2026
- Published by SAGE Publications in Toxicologic Pathology
Toxicologic Pathology Forum: ESTP/STP Working Group Opinion on the Evolving Landscape of New Approach Methodologies in Drug and Chemical Safety Development
In April 2025, the US Food and Drug Administration (FDA) introduced a bold roadmap to phase out animal testing in drug development by promoting the integration of New Approach Methodologies (NAMs), beginning with monoclonal antibodies (mAbs). Similar roadmaps have also been created by European health authorities and chemical safety agencies around the globe. This opinion paper from the European Society of Toxicologic Pathology and US Society of Toxicologic Pathology complex in vitro model and pathology working groups provides a balanced and expert perspective on the promise and limitations of these initiatives. NAMs, including in vitro, in silico, and refined in vivo models, offer exciting opportunities to improve human relevance, efficiency, and ethical standards in nonclinical safety assessment. While these approaches are already making meaningful contributions, current scientific and technical limitations prevent them from fully replacing animal studies in all contexts. At this time, NAMs should be viewed as powerful complementary tools whose appropriate integration depends on the context of use, validation, and continued collaboration across disciplines. Pathologists and investigative molecular pathology leaders are uniquely positioned to support this transition by bridging traditional methods with emerging technologies to enhance the safety and effectiveness of future therapeutics.
- 28 August 2026
- Published by SAGE Publications in Toxicologic Pathology
Toxicologic Pathology Forum: ESTP/STP Working Group Opinion on the Evolving Landscape of New Approach Methodologies in Drug and Chemical Safety Development
In April 2025, the US Food and Drug Administration (FDA) introduced a bold roadmap to phase out animal testing in drug development by promoting the integration of New Approach Methodologies (NAMs), beginning with monoclonal antibodies (mAbs). Similar roadmaps have also been created by European health authorities and chemical safety agencies around the globe. This opinion paper from the European Society of Toxicologic Pathology and US Society of Toxicologic Pathology complex in vitro model and pathology working groups provides a balanced and expert perspective on the promise and limitations of these initiatives. NAMs, including in vitro, in silico, and refined in vivo models, offer exciting opportunities to improve human relevance, efficiency, and ethical standards in nonclinical safety assessment. While these approaches are already making meaningful contributions, current scientific and technical limitations prevent them from fully replacing animal studies in all contexts. At this time, NAMs should be viewed as powerful complementary tools whose appropriate integration depends on the context of use, validation, and continued collaboration across disciplines. Pathologists and investigative molecular pathology leaders are uniquely positioned to support this transition by bridging traditional methods with emerging technologies to enhance the safety and effectiveness of future therapeutics.
- Open Access
Deep learning design and in vivo validation of Müller glia-specific cis -regulatory elements
Effective recombinant adeno-associated virus gene therapies require promoters that are compact and cell-type-specific. Ideally, promoters should also exhibit functional conservation when tested in model organisms to ensure that preclinical findings translate reliably to human patients. Here, we introduce a deep learning framework for designing cis -regulatory elements (CREs) meeting these criteria, applied to retinal Müller glia (MG). Using single-cell chromatin accessibility data from human and mouse retinas, we trained species-specific models to predict cell-type accessibility, and designed compact CREs using two complementary strategies. In silico validation predicted that the designed CREs exhibit high MG-specific accessibility (on-target) in both species with minimal off-target accessibility across hundreds of human cell types and tissues. Mechanistic analysis revealed that the predicted MG accessibility is driven by the creation of LHX2 motifs. In vivo validation confirmed that the designed CREs successfully restrict reporter expression to MG in the murine retina. Our deep learning framework is highly generalizable and enables the rapid design of compact, on-target, and species-conserved CREs for precision gene therapy.
Open AccessDeep learning design and in vivo validation of Müller glia-specific cis -regulatory elements
Effective recombinant adeno-associated virus gene therapies require promoters that are compact and cell-type-specific. Ideally, promoters should also exhibit functional conservation when tested in model organisms to ensure that preclinical findings translate reliably to human patients. Here, we introduce a deep learning framework for designing cis -regulatory elements (CREs) meeting these criteria, applied to retinal Müller glia (MG). Using single-cell chromatin accessibility data from human and mouse retinas, we trained species-specific models to predict cell-type accessibility, and designed compact CREs using two complementary strategies. In silico validation predicted that the designed CREs exhibit high MG-specific accessibility (on-target) in both species with minimal off-target accessibility across hundreds of human cell types and tissues. Mechanistic analysis revealed that the predicted MG accessibility is driven by the creation of LHX2 motifs. In vivo validation confirmed that the designed CREs successfully restrict reporter expression to MG in the murine retina. Our deep learning framework is highly generalizable and enables the rapid design of compact, on-target, and species-conserved CREs for precision gene therapy.
- 1 April 2026
- Published by Springer Nature
- Vol. 3023, 81-100
Ex Vivo Culture and Formalin-Fixed Paraffin Embedding of Murine Retinal Explants
Traumatic, inherited, and age-related degenerative diseases of the retina are characterized by irreversible loss of retinal neurons, and no present treatments are available to restore them. Cultured murine neuroretinal explants serve as a model of retinal injury and offer a high-throughput, ex vivo approach to test various therapeutic interventions. Here, we describe techniques to isolate and culture retinal explants and treat them with molecules and viruses to enable identification of novel therapeutic strategies. In order to assess the effectiveness of a potential intervention, we also describe protocols to handle friable retinal explants and prepare formalin-fixed paraffin-embedded sections for hematoxylin and eosin staining and immunofluorescence. We also provide tips to overcome common challenges in explant isolation, culture, embedding, and sectioning.
- 1 April 2026
- Published by Springer Nature
- Vol. 3023, 81-100
Ex Vivo Culture and Formalin-Fixed Paraffin Embedding of Murine Retinal Explants
Traumatic, inherited, and age-related degenerative diseases of the retina are characterized by irreversible loss of retinal neurons, and no present treatments are available to restore them. Cultured murine neuroretinal explants serve as a model of retinal injury and offer a high-throughput, ex vivo approach to test various therapeutic interventions. Here, we describe techniques to isolate and culture retinal explants and treat them with molecules and viruses to enable identification of novel therapeutic strategies. In order to assess the effectiveness of a potential intervention, we also describe protocols to handle friable retinal explants and prepare formalin-fixed paraffin-embedded sections for hematoxylin and eosin staining and immunofluorescence. We also provide tips to overcome common challenges in explant isolation, culture, embedding, and sectioning.
- 9 December 2024
- Published by Wiley in Histopathology
- Vol. 86 (5) , 779-792
Serous‐like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours
Aims: Unusual morphologic patterns of breast carcinomas can raise diagnostic consideration for metastasis or special breast cancer subtypes with management implications. We describe rare invasive breast cancers that mimic serous carcinoma of the gynaecologic tract (serous‐like breast carcinomas, SLBC) and characterize their clinicopathologic, immunophenotypic, and genetic features.Methods and Results: All patients were female (n = 15, median age 49 years) without a history of gynaecologic malignancy. SLBC were characterized histologically by angulated, branched, sometimes anastomosing glands with micropapillary and/or pseudopapillary luminal projections in desmoplastic stroma. Most SLBC were triple‐negative (TN, n = 10) or HER2‐positive (n = 2) and grade 2 or 3, while some were oestrogen receptor (ER) low‐positive/HER2‐negative and low‐grade (n = 3). CK5/6 was positive irrespective of grade or receptor status (10/10). All SLBC expressed GATA3 (14/15), TRPS1 (7/7), and/or mammaglobin (4/13). SOX10 was positive in most TN (9/10) and all ER low‐positive (3/3) cases, but negative in HER2‐positive tumours. WT1 was universally negative, and PAX8 was focal in one mammaglobin‐positive tumour. All ER‐negative SLBC were p53‐aberrant and 9/11 were p16‐aberrant, whereas ER‐positive tumours were wildtype for both markers (3/3). TP53 was the only frequently mutated gene, altered in all ER‐negative (10/10) but no ER‐positive (0/4) tumours. Clinical behaviour was variable. Only 1/6 patients achieved pathologic complete response to neoadjuvant chemotherapy.Conclusion: SLBC is a rare morphologic pattern of invasive breast carcinoma that mimics metastatic serous gynaecologic carcinoma, a potential diagnostic pitfall. SLBC are heterogeneous with respect to grade, receptor profile, and oncogenic driver alterations, without specific genetic underpinnings identified. Additional studies are warranted to further evaluate the clinical behaviour of these tumours.
- 9 December 2024
- Published by Wiley in Histopathology
- Vol. 86 (5) , 779-792
Serous‐like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours
Aims: Unusual morphologic patterns of breast carcinomas can raise diagnostic consideration for metastasis or special breast cancer subtypes with management implications. We describe rare invasive breast cancers that mimic serous carcinoma of the gynaecologic tract (serous‐like breast carcinomas, SLBC) and characterize their clinicopathologic, immunophenotypic, and genetic features.Methods and Results: All patients were female (n = 15, median age 49 years) without a history of gynaecologic malignancy. SLBC were characterized histologically by angulated, branched, sometimes anastomosing glands with micropapillary and/or pseudopapillary luminal projections in desmoplastic stroma. Most SLBC were triple‐negative (TN, n = 10) or HER2‐positive (n = 2) and grade 2 or 3, while some were oestrogen receptor (ER) low‐positive/HER2‐negative and low‐grade (n = 3). CK5/6 was positive irrespective of grade or receptor status (10/10). All SLBC expressed GATA3 (14/15), TRPS1 (7/7), and/or mammaglobin (4/13). SOX10 was positive in most TN (9/10) and all ER low‐positive (3/3) cases, but negative in HER2‐positive tumours. WT1 was universally negative, and PAX8 was focal in one mammaglobin‐positive tumour. All ER‐negative SLBC were p53‐aberrant and 9/11 were p16‐aberrant, whereas ER‐positive tumours were wildtype for both markers (3/3). TP53 was the only frequently mutated gene, altered in all ER‐negative (10/10) but no ER‐positive (0/4) tumours. Clinical behaviour was variable. Only 1/6 patients achieved pathologic complete response to neoadjuvant chemotherapy.Conclusion: SLBC is a rare morphologic pattern of invasive breast carcinoma that mimics metastatic serous gynaecologic carcinoma, a potential diagnostic pitfall. SLBC are heterogeneous with respect to grade, receptor profile, and oncogenic driver alterations, without specific genetic underpinnings identified. Additional studies are warranted to further evaluate the clinical behaviour of these tumours.
- Open Access
- 5 September 2024
- Published by Taylor & Francis in Journal of Histotechnology
- Vol. 48 (1) , 46-57
Histogel-based techniques for embedding organoids in paraffin blocks enable high throughput downstream histopathological analyses
Organoids are in vitro tissue models derived from human or animal primary tissues or stem cells that allow for studying three-dimensional (3D) tissue biology, toxicity testing, biomarker evaluation, and assessment of compound efficacy, supplementing or potentially minimizing use of animal models. Organoids are typically cultured in a 3D format within an extracellular matrix and, at the end of an experiment, can be further processed for various cellular or molecular readouts. Analysis often relies on whole mount immunolabeling for markers of interest, which consumes the entire sample/well, thereby limiting sample availability for downstream assays. In addition, 3D cultures become more friable after fixation and are susceptible to sample loss during washing steps. In contrast, by fixing and processing organoids to a paraffin block, dozens or hundreds of unstained slides can be generated, enabling robust characterization via multiple assays, including histologic evaluation and (immuno)histochemical stains, thus maximizing the yield of these time- and labor-intensive cultures. Here we describe three methods to process 3D Matrigel cultures into paraffin blocks using Histogel as an embedding agent. The three techniques all yield high-quality sections but vary in complexity of implementation at different steps, and their application for different use cases is discussed.
- 5 September 2024
- Published by Taylor & Francis in Journal of Histotechnology
- Vol. 48 (1) , 46-57
Open AccessHistogel-based techniques for embedding organoids in paraffin blocks enable high throughput downstream histopathological analyses
Organoids are in vitro tissue models derived from human or animal primary tissues or stem cells that allow for studying three-dimensional (3D) tissue biology, toxicity testing, biomarker evaluation, and assessment of compound efficacy, supplementing or potentially minimizing use of animal models. Organoids are typically cultured in a 3D format within an extracellular matrix and, at the end of an experiment, can be further processed for various cellular or molecular readouts. Analysis often relies on whole mount immunolabeling for markers of interest, which consumes the entire sample/well, thereby limiting sample availability for downstream assays. In addition, 3D cultures become more friable after fixation and are susceptible to sample loss during washing steps. In contrast, by fixing and processing organoids to a paraffin block, dozens or hundreds of unstained slides can be generated, enabling robust characterization via multiple assays, including histologic evaluation and (immuno)histochemical stains, thus maximizing the yield of these time- and labor-intensive cultures. Here we describe three methods to process 3D Matrigel cultures into paraffin blocks using Histogel as an embedding agent. The three techniques all yield high-quality sections but vary in complexity of implementation at different steps, and their application for different use cases is discussed.
- Open Access
- 18 October 2023
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 8 (1) , 1-15
Epimorphic regeneration in the mammalian tympanic membrane
Adult mammals are generally believed to have limited ability to regenerate complex tissues and instead, repair wounds by forming scars. In humans and across mammalian species, the tympanic membrane (TM) rapidly repairs perforations without intervention. Using mouse models, we demonstrate that the TM repairs itself through a process that bears many hallmarks of epimorphic regeneration rather than typical wound healing. Following injury, the TM forms a wound epidermis characterized by EGFR ligand expression and signaling. After the expansion of the wound epidermis that emerges from known stem cell regions of the TM, a multi-lineage blastema-like cellular mass is recruited. After two weeks, the tissue architecture of the TM is largely restored, but with disorganized collagen. In the months that follow, the organized and patterned collagen framework of the TM is restored resulting in scar-free repair. Finally, we demonstrate that deletion of Egfr in the epidermis results in failure to expand the wound epidermis, recruit the blastema-like cells, and regenerate normal TM structure. This work establishes the TM as a model of mammalian complex tissue regeneration.
- 18 October 2023
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 8 (1) , 1-15
Open AccessEpimorphic regeneration in the mammalian tympanic membrane
Adult mammals are generally believed to have limited ability to regenerate complex tissues and instead, repair wounds by forming scars. In humans and across mammalian species, the tympanic membrane (TM) rapidly repairs perforations without intervention. Using mouse models, we demonstrate that the TM repairs itself through a process that bears many hallmarks of epimorphic regeneration rather than typical wound healing. Following injury, the TM forms a wound epidermis characterized by EGFR ligand expression and signaling. After the expansion of the wound epidermis that emerges from known stem cell regions of the TM, a multi-lineage blastema-like cellular mass is recruited. After two weeks, the tissue architecture of the TM is largely restored, but with disorganized collagen. In the months that follow, the organized and patterned collagen framework of the TM is restored resulting in scar-free repair. Finally, we demonstrate that deletion of Egfr in the epidermis results in failure to expand the wound epidermis, recruit the blastema-like cells, and regenerate normal TM structure. This work establishes the TM as a model of mammalian complex tissue regeneration.
- Open Access
- 2 October 2022
- Published by Taylor & Francis in Journal of Histotechnology
- Vol. 45 (4) , 182-194
Improved handling and embedding schemes for cultured murine neuroretinal explants
Traumatic, inherited, and age-related degenerative diseases of the retina, such as retinal detachment, retinitis pigmentosa, and age-related macular degeneration, are characterized by the irreversible loss of retinal neurons. While current treatments aim to prevent neuronal degeneration, there are no available treatments to restore neurons after loss. Cultured murine neuroretinal tissue explants model retinal injury and offer a high throughput approach to identify experimental interventions capable of regenerating neurons. Formalin-fixed paraffin-embedded (FFPE) preparations of murine neuroretinal explants can be used to identify cells throughout the retinal layers to provide information on proliferation and activity following exposure to therapeutics. However, retinal explants are friable, particularly after ex vivo culture, sample handling and FFPE processing steps can result in tissue loss and damage. Friability also prohibits bisecting samples post-culture to display more than one region of interest for analysis. We developed a sample handling and embedding technique for cultured murine neuroretinal explants using HistogelTM in combination with a post-processing trimming step that eliminates tissue loss, increases cross-sectional retinal representation, and captures proximal and central retina on one slide to facilitate analysis of explants subjected to neurotrophic compounds.
- 2 October 2022
- Published by Taylor & Francis in Journal of Histotechnology
- Vol. 45 (4) , 182-194
Open AccessImproved handling and embedding schemes for cultured murine neuroretinal explants
Traumatic, inherited, and age-related degenerative diseases of the retina, such as retinal detachment, retinitis pigmentosa, and age-related macular degeneration, are characterized by the irreversible loss of retinal neurons. While current treatments aim to prevent neuronal degeneration, there are no available treatments to restore neurons after loss. Cultured murine neuroretinal tissue explants model retinal injury and offer a high throughput approach to identify experimental interventions capable of regenerating neurons. Formalin-fixed paraffin-embedded (FFPE) preparations of murine neuroretinal explants can be used to identify cells throughout the retinal layers to provide information on proliferation and activity following exposure to therapeutics. However, retinal explants are friable, particularly after ex vivo culture, sample handling and FFPE processing steps can result in tissue loss and damage. Friability also prohibits bisecting samples post-culture to display more than one region of interest for analysis. We developed a sample handling and embedding technique for cultured murine neuroretinal explants using HistogelTM in combination with a post-processing trimming step that eliminates tissue loss, increases cross-sectional retinal representation, and captures proximal and central retina on one slide to facilitate analysis of explants subjected to neurotrophic compounds.
- 1 March 2019
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 43 (3) , 399-408
Pleomorphic and Florid Lobular Carcinoma In Situ Variants of the Breast
The natural history and optimal treatment of pleomorphic (PLCIS) and florid (FLCIS) lobular carcinoma in situ variants remains uncertain. We reviewed the clinicopathologic features and management of LCIS variants at our institution over a 20-year period. Of 85 cases (61 PLCIS, 24 FLCIS), 77% were associated with invasive carcinoma (84% lobular, 13% ductal/lobular, 3% ductal) and only 17% (9 PLCIS, 5 FLCIS) were pure. Most (81%) invasive carcinomas were grade 2, with all grade 3/pleomorphic invasive lobular carcinomas (ILC) associated with PLCIS, and all grade 1 tumors associated with FLCIS. PLCIS-associated invasive carcinomas were more often ER− (21%) or HER2+ (14%) than FLCIS-associated tumors (100% ER+, 6% HER2+). LCIS variants were unifocal and co-localized with invasive carcinoma in 20/20 selected spatially mapped cases, whereas classic LCIS (CLCIS) was multifocal with wider distribution (10/17). Of 21 pure LCIS variants on core biopsy, all represented the radiographic (95%) or palpable (5%) target. The excisional upgrade rate was similar for PLCIS (38%) and FLCIS (33%). Pure LCIS variants on core biopsy were often (20%) HER2+ and had a higher Ki-67-index than synchronous CLCIS (P=0.002). Lower ER expression in LCIS variants versus CLCIS was due to ER− apocrine PLCIS. ER and HER2 were consistently concordant between LCIS variants and upgraded ILC but discordant between synchronous CLCIS and LCIS variants in 5/14 (36%). Pure LCIS variants were excised to negative margins and frequently (58%) treated with endocrine but not radiation therapy without recurrences. In summary, PLCIS and FLCIS demonstrate features of direct precursor lesions warranting surgical excision.
- 1 March 2019
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 43 (3) , 399-408
Pleomorphic and Florid Lobular Carcinoma In Situ Variants of the Breast
The natural history and optimal treatment of pleomorphic (PLCIS) and florid (FLCIS) lobular carcinoma in situ variants remains uncertain. We reviewed the clinicopathologic features and management of LCIS variants at our institution over a 20-year period. Of 85 cases (61 PLCIS, 24 FLCIS), 77% were associated with invasive carcinoma (84% lobular, 13% ductal/lobular, 3% ductal) and only 17% (9 PLCIS, 5 FLCIS) were pure. Most (81%) invasive carcinomas were grade 2, with all grade 3/pleomorphic invasive lobular carcinomas (ILC) associated with PLCIS, and all grade 1 tumors associated with FLCIS. PLCIS-associated invasive carcinomas were more often ER− (21%) or HER2+ (14%) than FLCIS-associated tumors (100% ER+, 6% HER2+). LCIS variants were unifocal and co-localized with invasive carcinoma in 20/20 selected spatially mapped cases, whereas classic LCIS (CLCIS) was multifocal with wider distribution (10/17). Of 21 pure LCIS variants on core biopsy, all represented the radiographic (95%) or palpable (5%) target. The excisional upgrade rate was similar for PLCIS (38%) and FLCIS (33%). Pure LCIS variants on core biopsy were often (20%) HER2+ and had a higher Ki-67-index than synchronous CLCIS (P=0.002). Lower ER expression in LCIS variants versus CLCIS was due to ER− apocrine PLCIS. ER and HER2 were consistently concordant between LCIS variants and upgraded ILC but discordant between synchronous CLCIS and LCIS variants in 5/14 (36%). Pure LCIS variants were excised to negative margins and frequently (58%) treated with endocrine but not radiation therapy without recurrences. In summary, PLCIS and FLCIS demonstrate features of direct precursor lesions warranting surgical excision.
- 3 February 2019
- Published by Wiley in Pediatric Transplantation
- Vol. 23 (3) , e13371
De novo leukocyte chemotactic factor 2 amyloidosis in a pediatric renal allograft, 15 years post‐transplant
Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a recently described form of systemic amyloidosis, which most commonly affects the kidney and liver. The LECT2 protein is produced during inflammatory processes, but its precise function in renal diseases in unclear. ALECT2, however, is known to be a relatively common form of renal amyloidosis, after amyloid light chain and serum amyloid A types and is most often seen in patients of Hispanic ethnicity. ALECT2 can occur de novo or as recurrent disease in kidney transplants. We present the first case, to our knowledge, of de novo ALECT2 in a pediatric kidney transplant patient, 15 years post‐transplant.
- 3 February 2019
- Published by Wiley in Pediatric Transplantation
- Vol. 23 (3) , e13371
De novo leukocyte chemotactic factor 2 amyloidosis in a pediatric renal allograft, 15 years post‐transplant
Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a recently described form of systemic amyloidosis, which most commonly affects the kidney and liver. The LECT2 protein is produced during inflammatory processes, but its precise function in renal diseases in unclear. ALECT2, however, is known to be a relatively common form of renal amyloidosis, after amyloid light chain and serum amyloid A types and is most often seen in patients of Hispanic ethnicity. ALECT2 can occur de novo or as recurrent disease in kidney transplants. We present the first case, to our knowledge, of de novo ALECT2 in a pediatric kidney transplant patient, 15 years post‐transplant.